Printer Friendly

King LASIK centres to offer Avellino Lab USA's genetic test for Granular Corneal Dystrophy.

M2 PHARMA-July 8, 2014-King LASIK centres to offer Avellino Lab USA's genetic test for Granular Corneal Dystrophy


8 July 2014 - Avellino Lab USA, a developer of genetic diagnostics systems, said Tuesday that King LASIK, a full service eye care centre with seven Pacific Northwest locations, would start offering the Avellino DNA Dual Test for LASIK Safety for the detection of Granular Corneal Dystrophy type 1 (GCD1) and type 2 (GCD2).

GCD typically develops slowly, but people with this genetic mutation are at a very high risk of accelerated opacity formations if they have vision-correction surgery, including LASIK, LASEK or PRK. The Avellino DNA Dual Test for LASIK Safety detects with high accuracy if an individual carries the genetic mutation, thus lowering the risk of patients with the GCD mutation to have post-LASIK vision impairment.

The test uses a simple mouth swab to detect if an individual has the GCD1 or the GCD2 gene mutation. In particular, the ophthalmologist collects ten swipes from the inside of each cheek to obtain an adequate sample, which is then sent to Avellino Lab USA, and within up to 48 hours, the findings are returned to the King LASIK clinician. Based on a negative result, patients can proceed with the planned LASIK procedure, while in case of positive results for the genetic mutation, the person will be advised against undergoing LASIK surgery and advised to take protective measures, including minimising exposure to UV light by wearing protective lenses to help delay the progression of GCD symptoms.

((Comments on this story may be sent to

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 8, 2014
Previous Article:University of Iowa scientists find early biomarker of preeclamptic pregnancy.
Next Article:BioDiscovery wins NIH grant to improve CNV data from The Cancer Genome Atlas.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |